Summary
The effects of piroxicam (40 mg) on the pharmacokinetics of ranitidine (150 mg) and of ranitidine (150 mg bid) on the pharmacokinetics of piroxicam (20 mg) were assessed in two 2-way crossover studies in two groups of 18 healthy male subjects.
In the first study there were no statistically significant differences between the pharmacokinetic variables for ranitidine in the presence or absence of piroxicam. The mean maximum plasma concentration (Cmax) was 467 ng·ml−1 for ranitidine alone and 466 ng·ml−1 in the presence of piroxicam; mean area under the plasma concentration vs time curve (AUC) was 2460 h·ng ml−1 and 2551 h·ng ml−1 respectively; and the mean terminal half-life (t 1/2) was 3.6 h and 3.8 h respectively.
In the second study there were no statistically significant differences between the pharmacokinetic variables for piroxicam in the presence or absence of ranitidine. The mean Cmax was 2.1 μ·ml−1 in the presence of placebo and 2.0 μg·ml−1 in the presence of ranitidine respectively; mean AUC was 133 h·μg ml−1 and 137 h·μg ml−1 respectively, and the mean t 1/2 was 53.6 h and 54.5 h respectively.
Similar content being viewed by others
References
CSM Update (1986) Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions-2. Br J Med 292: 1190–1191
Delhotal-Landes B, Flouvat B, Liote F, Abel L, Meyer P, Vinceneux P, Carbon C (1988) Pharmacokinetic interactions between NSAIDs (indomethacin or sulindac) and H2-receptor antagonists (cimetidine or ranitidine) in human volunteers. Clin Pharmacol Ther 44: 442–452
Hill M, Armitage P (1979) Two period cross-over clinical trial. Br J Clin Pharmacol 8: 7–20
Koch GG (1972) The use of non-parametric methods in the statistical analysis of the two period change-over design. Biometrics 28: 577–584
Larkai EN, Smith JL, Lidsky MD, Graham DI (1987) Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 82: 1153–1158
Mailhot C, Dahl SL, Ward JR (1986) The effect of cimetidine on serum concentrations of piroxicam. Pharmacotherapy 6: 112–117
Ochs HR, Greenblatt DJ, Matlis R, Weinbrenner J (1985) Interaction of ibuprofen with the H2-receptor antagonists ranitidine and cimetidine. Clin Pharmacol Ther 38: 648–651
Pabst G, Jaeger H (1990) Review of methods and criteria for the evaluation of bioequivalence studies. Eur J Clin Pharmacol 38: 5–10
Pitts N (1980) Review of clinical trial experience with piroxicam. Piroxicam a new NSAID. Proceedings of a symposium at the IXth European Congress of Rheumatology, Wiesbaden, 1979. Academy Professional Information Services, New York, pp 48–66
Richardson CJ, Ross SG, Blocka KL, Berbeek RK (1986) High performance liquid chromatographic analysis of piroxicam and its major metabolite, 5-Hydroxypiroxicam, in human plasma and urine. J Chromatogr 382: 382–388
Said SA, Foda AM (1989) Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man. Arzneim-Forsch/Drug Res 39: 790–792
Sullivan KM, Small RE, Rock WL, Cox SR, Willis HE (1986) Effects of cimetidine or ranitidine on the pharmacokinetics of flurbiprofen. Clin Pharmacy 5: 586–589
Twomey TM, Bartolucci SR, Hobbs DC (1980) Analysis of piroxicam in plasma by high-performance liquid chromatography. J Chromatogr 183: 104–108
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dixon, J.S., Lacey, L.F., Pickup, M.E. et al. A lack of pharmacokinetic interaction between ranitidine and piroxicam. Eur J Clin Pharmacol 39, 583–586 (1990). https://doi.org/10.1007/BF00316100
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00316100